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Abstract 
Progressin development of tuberculosis (TB) vaccines largely depends on the availability of animal models to test their safety 
and efficacy before starting with expensive clinical trials. The present study provides a comprehensive evaluation of bacillus 
Calmette-Guerin (BCG) effects on clinical, immunological, pathological and bacteriological parameters in goats after an 
experimental challenge with Mycobacterium caprae.Vaccination of goats with BCG reduced the volume of lung gross lesions, 
the bacterial load in pulmonary lymph nodes and increased the weight gain when compared to unvaccinated animals. Differences 
in post-challenge IFN-γ responses to ESAT-6/CFP-10 were found to be a useful follow-up biomarker of disease progression and 
vaccine efficacy. Our results endorse this animal model for further TB vaccine trials. 
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Introduction 
 
The domestic goat is a natural host of tuberculosis (TB). Caprine TB is an emerging zoonotic disease in many 
European countries[1,2]. Vaccination could be taken into consideration as an alternative to test-and-slaughter 
strategy for long-term TB control in livestock [3]. Moreover, the use in vaccine trials of experimental animals that 
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are as well natural hosts of TB, such as goats, may be essential for a better understanding of mechanisms involved in 
protection and the development of new vaccines and therapies [4–6]. 
Currently, bacillus Calmette-Guérin (BCG) is the only licensed vaccine against human TB and is also being 
included in TB vaccine clinical trials. The majority of new prophylactic vaccine candidates in clinical trials are 
designed either as recombinant BCG vaccines oras subunit vaccines for use after a previous immunization with 
BCG[7–9]. 
Small laboratory animal models are usually employed in preliminary screeningsfor new vaccine candidates. 
However, larger animals, which efficiently reproduce the main features of human TB, are required in subsequent 
steps for developing TB vaccines.Domestic goats are easy to house in BSL-3 conditions, involve relatively low 
maintenance costs compared to other large mammals and, importantly, develop similar TB lesions and 
immunological responses  than  active diseased human patients[4].    
The aim of this study was to assess the potential use of theexperimental goat model inTB vaccine trials. 
Comparison of ante-mortem and post-mortem parameters was carried out in BCG vaccinated and unvaccinated goats 
after beingchallenged with M. caprae,which is the main causative agent of caprine TB in Spain [2] 
 
 
Materials and methods 
 
Experimental schedule 
 
Eleven goat kids were vaccinated with 5×105 CFU of BCG Danish strain, and other 11 goat kids remained as non-
vaccinated control group. Fifteen weeks later, all goats were anesthetized as previously described [4]and challenged 
with approximately 1.5×103 CFU of M. caprae through the endobronchial route.After challenge, goats were weighed 
weekly throughout the experiment. Blood samples were taken at weeks 0, 5, 11 and 13 post-challenge. All goats 
were euthanized and subsequently necropsied at 13 weeks post-challenge. All animal experimental procedures were 
undertaken in accordance with  the European Union Laws for protection of experimental animals (86/609), and 
ethical approval was obtained from the Animal Welfare Committee of the Government of Catalonia (Permit 
Number: 6332). 
 
Antigen-specificIFN-γ responses  
 
One ml of whole blood from each animal was stimulated in 96-deepwell cell culture plates (Eppendorf Ibérica, 
Madrid, Spain) withand ESAT-6/CFP-10 peptide cocktail at a final concentration of 5 μg/ml.Phosphate buffered 
saline was added to another ml of whole blood, which was used as unstimulated control.Blood cultures were 
incubated overnight at 37qC and 5% CO2.  Afterwards, plasma supernatants were collectedand tested by using a 
commercial IFN-γ sandwichenzyme-linked immunosorbent assay(Bovigam®, Prionics, Switzerland). Results were 
obtained as Optical Density determined at 450 nm (OD450). Specific reaction was expressed as ΔOD450 (OD450 of 
ESAT-6/CFP-10-stimulated sample minus OD450 of non-stimulated sample). 
 
Post-mortem examination and bacteriological culture 
 
After necropsy, lungs were removed and fixed through intra-tracheal perfusion and immersion in 10%-buffered 
formalin and, thereafter, were scanned with a multi-detector computed tomography (CT) scanner (Brillance CT 64-
channel, Philips Medical Systems, Cleveland, Ohio, USA). TB lesions were analyzed on a work station (Aquarius 
Station, TaraRecon, Foster City, California, USA) and the total volume of lung gross lesions was calculated. Whole 
pulmonary lymph nodes (cranial and caudal mediastinal, and tracheobronchial) were collected, homogenized and 
cultured for bacterial count as previously described [4].  
 
Data analysis 
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Statistical analysis was performed using Deducer-R-2.15.0 package.Comparisons between vaccinated and 
unvaccinated groups were assessed with Student’s unpaired two-sample T-test (differences in weight increase, 
volume of gross lesions and log10CFU) and the non-parametric Mann-Withney test (differences in ΔOD450ofwhole 
blood IFN-γ responses).  
 
 
Results 
 
Body weight findings 
 
Vaccinated goats showed higher increase of mean weight gain compared to the unvaccinated group after 
experimental infection (Fig. 1A). At the end point of the experiment (13 weeks post-infection), the mean weight gain 
of vaccinated goats was 4.9 kg (3.9-5.9 95% CI), being significantly higher than the mean weight gain of 
unvaccinated goats (3.5 kg, 2.8-4.8 95% CI,P = 0.021).  
 
Immunological findings 
 
Immunologicalresponses toM. caprae infection, measured as IFN-γ levels of samples stimulated with ESAT-
6/CFP-10 peptide cocktail were higher in unvaccinated animals, particularly at 5 weeks post-infection(P = 0.001, 
Fig1B).ESAT-6/CFP-10-specific IFN-γ levels were undetectable in both vaccinated and unvaccinated goats prior to 
M. capraechallenge (15 weeks post-vaccination). 
 
 
Fig. 1. (a) Average weight increase after M. caprae challenge; BCG, vaccinated group; Control, non-vaccinated group. *P< 0.05 (unpaired 
two-sample T-test). (b)Whole blood IFN-γ responses to ESAT-6/CFP-10 after M. caprae challenge. **P< 0.01 (Mann-Withney test). 
 
 
Post-mortem findings 
 
At necropsy, all animals showed TB lesions in lungs and pulmonary lymph nodes irrespectively of the 
experimental group. CT analysis of the lungs allowed the total volume of gross lesions calculation (Fig. 2). 
Vaccinated animals showed significant lower extension of pulmonary lesions compared to unvaccinated controls 
(P < 0.001, Fig. 3A). Significant reduction of bacterial load in pulmonary lymph nodes was also found in the 
vaccinated group (P < 0.001, Fig. 3B). 
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Fig. 2. (a) Right lung of an unvaccinated goat with TB lesions in the right diaphragmatic lobe. (b) Volumetric 3-D reconstruction of the whole 
lung. The lung volume is shown in the red-dashed box. (c)Volumetric 3-D reconstruction showing different tissue densities discriminated by 
color: air in black, liquid in grey and lesions in red. (d) Volume rendering image of lesions. The total volume of lung lesions is shown in the red-
dashed box. 
 
 
 
 
 
 
 
 
47 Bernat Pérez de Val et al. /  Procedia in Vaccinology  8 ( 2014 )  43 – 49 
 
Fig. 3. (a) Individual volumes of lung gross lesions. (b) Individual bacterial counts in pulmonary lymph nodes. Dashed lines indicate mean 
values of each group. ***P< 0.001(unpaired two-sample T-test) 
 
 
Discussion 
 
Experimental animal models used for testing TB vaccines should reproduce features of human TB. Small 
laboratory animals (mice or guinea pigs) have been used in TB vaccine trials but these results cannot often be 
translated into larger mammals. In the present study, all unvaccinated goats developed advanced human-like 
pulmonary TB only 13 weeksafter challenge, accordingly to previously described in M. capraeexperimentally 
infected goats[4]. In contrast, smaller lung lesions found in BCG vaccinated animals allowed the assessment of 
vaccine protective efficacy. 
 
After small laboratory animals, non-human primates (NHP) arethe animal model mainly usedto test human TB 
vaccine candidates [8], however, there are economic, logistic, and ethical limitations for extensive use of NHP. The 
bovine model has alsobeen used to test human TB vaccines [10], but cattle are expensive to maintain and difficult to 
manage, particularly, in highbio-containment conditions. Moreover, experimental infections in cattle rarely induce 
lung cavitary lesions [11].On the contrary, goats are smaller, less expensive, and, in the present work, 
allunvaccinated animals producedbig coalescent and caseous granulomatous and cavitary lesions, similar to those 
found in human patients with active disease [4]. 
 
Differences in body weight, gross pathology and bacterial loadobserved between groups can be used to assess 
vaccine efficacy. Unvaccinated goats showed a reduction of weight gain, bigger and more disseminated gross lesions 
in lungs, and higher bacterial burden in pulmonary lymph nodes in comparison to vaccinated goats. These results are 
indicative of protection conferred by BCG.Similar results were previously found in BCG efficacy experimental trials 
conducted in other natural hosts of TB, such as calves [12], badgers[13], possums [14], white-tailed deer [15]or wild 
boar [16]. 
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The lower IFN-γ responses against antigens secreted by the growing bacilli (i.e. ESAT-6 and CFP-10) found in 
vaccinated animals (mainly at 5 weeks post-challenge) is consistent with the lower bacterial load and gross 
pathology found in the vaccinated group. These results are in agreement with those previously found in goats [4], 
calves [17] and humans [18]. 
 
In summary, the advantages the goat model presented herein are that (i) goats are a natural host of infection, (ii) 
tuberculosis isreproduced with a high efficiency using a low dose of mycobacteria in a large mammal, (iii) there is a 
hightendency to production of cavernous lesions, similar to the situation in lungs from human patients with 
activedisease, (iv) All pulmonary tuberculous lesions can be quantitatively evaluated by CT (v) whole bacterial load 
can be measured in respiratory lymph nodes, and (vi) the experimentalsetting is much cheaper compared to NHP or 
cattle. 
 
The results obtained in the present study endorse the potential use of goats as an experimental animal model to 
test the efficacy of new TB vaccine candidates. 
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